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Abstract EPAS1 is a hypoxia-inducible transcription factor,
highly expressed in vasculature and recently shown to be
necessary for catecholamine production during embryogenesis.
We report here the cloning and detailed expression pattern of this
factor in the chicken embryo. We show that chicken EPAS1
presents an overall identity of 76% with the human sequence and
that it is strongly expressed in the blood vessel wall, mostly in
endothelial cells, but also in vascular smooth muscle cells.
Moreover, we report non-vascular expression sites : liver, kidney,
and, quite interestingly, cells of the sympathetic nervous system
where EPAS1 is coexpressed with one of its putative target
genes, the tyrosine hydroxylase. EPAS1 could therefore
represent the link between the vascular system and the
sympathetic nervous system, both sensitive to hypoxia.
z 1999 Federation of European Biochemical Societies.
Key words: EPAS1; Hypoxia-inducible factor 2K ; Hypoxia;
Tyrosine hydroxylase; Angiogenesis ; Gallus gallus
1. Introduction
The family of proteins harboring a basic helix-loop-helix
PAS (bHLH-PAS) domain (for review see [1]) constitutes a
class of transcription factors encompassing a broad range of
functions, mostly in di¡erentiation and metabolic processes.
Thus, they regulate genes involved in neurogenesis [Single-
minded (Sim), NPAS], xenobiotic metabolism [aryl hydrocar-
bon receptor (AHR)], control of circadian rhythm [Period
(Per), Clock, Timeless], tracheal formation [trachealess (trh)]
and response to low oxygen tension [hypoxia-inducible factor
1K (HIF1K)]. All family members comprise a bHLH domain
implicated in DNA binding and dimerization, located in the
amino-terminus of a PAS domain. The PAS (Per-Arnt-Sim)
region which displays two hydrophobic repeat motifs (A and
B) functions as a dimerization interface.
Endothelial PAS protein 1 (EPAS1) is a member of the
bHLH-PAS family recently identi¢ed in human [2], mouse
[2] and bovine [3] species. It has also been reported as
HIF1K-like factor (HLF) [4], HIF1K-related factor (HRF)
[5], member of PAS superfamily 2 (MOP2) [6] and HIF2K
[7]. The primary amino acid sequence of EPAS1 is 48% iden-
tical to that of HIF1K. Like HIF1K, EPAS1 can form active
heterodimers with ARNT (aryl hydrocarbon receptor nuclear
translocator) [2] and ARNT3 [8], and transactivate the expres-
sion of a reporter gene containing HREs (hypoxia responsive
elements) in the promoter region. In transfection assays, this
activity is enhanced 2^4-fold in hypoxic conditions (1% O2)
[2], mediated by an accumulation of EPAS1 protein ^ but not
mRNA ^ [9], as previously shown for HIF1K [10,11].
Although these two transcription factors seem to share com-
mon functional mechanisms in vitro, their patterns of expres-
sion studied in the mouse suggest that they play di¡erent and
perhaps complementary roles during embryogenesis. In the
mouse fetus, the expression of HIF1K is ubiquitous and
does not seem to be speci¢c to any cell or tissue type [12],
unlike EPAS1 which is particularly expressed in endothelial
cells (ECs) [2,5,12]. HIF1K has been previously shown to be
necessary for both embryonic and tumoral angiogenesis [13^
15]. The high homology of EPAS1 with HIF1K together with
its increased activity under hypoxic conditions and its vascular
expression pattern suggested an important role in regulation
of angiogenesis. Moreover, EPAS1 displays activity on the
promoters of three genes known to be essential for angiogen-
esis, i.e. the vascular endothelial growth factor (VEGF) [4,9],
its receptor Flk-1 [16] and the endothelial receptor Tie2 [2].
These observations still further point to a central role of
EPAS1 in blood vessel formation.
Unexpectedly, the recent results of EPAS1 gene inactivation
in the mouse [17] revealed a crucial role of this factor, not in
vascular formation, but in catecholamine production. Indeed,
EPAS13/3 mice die of heart failure between day 12 and 16 of
embryonic development, a probable consequence of a pro-
foundly reduced level of norepinephrine. These observations
pointed toward other potential target genes to be regulated by
EPAS1 such as tyrosine hydroxylase (TH) and dopamine
L-hydroxylase, two key enzymes implicated in catecholamine
release and known to be overexpressed during hypoxia [18,19].
Discrepancies between the importance of EPAS1 in angio-
genic processes as suggested by both in vitro and in situ stud-
ies and the results obtained in vivo remain to be clari¢ed. To
address these questions, we have undertaken a study of this
transcription factor using an experimental model well estab-
lished for the study of development and particularly angio-
genesis, the chicken embryo. We have cloned the avian homo-
logue of EPAS1 and studied its expression during chicken
development. We report here that both the sequence and
the expression pattern reveal a high conservation of EPAS1
between mammals and avian species. Moreover, our observa-
tions also show a precise colocalization of this transcription
factor with TH in cells of the sympathetic system. The coex-
pression of EPAS1 and TH provides a simple explanation for
the lethality due to insu⁄cient levels of catecholamine ob-
served in EPAS13/3 mice and strongly suggests a direct
regulation of TH by EPAS1 under normal or hypoxic condi-
tions.
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2. Materials and methods
2.1. Cloning of cEPAS1
2.1.1. RT-PCR. Total RNAs were extracted from chicken lung
according to the method of Chomczynski and Sacchi [20]. One Wg
of total RNA was reverse transcribed in a 20 Wl reaction volume
for 1 h at 37‡C, using the MMLV reverse transcriptase (Gibco-
BRL) as described by the manufacturer. Primers used to amplify
the chicken EPAS1 cDNA (A: 5P-AGCAAGACCTTCCTGAGCC-
GC-3P ; B: 5P-GGTGACTCTTGGTCATGTTCTC-3P) were designed
from the human sequence and corresponded to the highly conserved
domain PAS-B. The PCR reaction was performed as follows, on a
Perkin Elmer Cetus 480 thermal cycler: the cDNAs were denatured
(94‡C for 5 min), subjected to 30 cycles of ampli¢cation (94‡C for
1 min, 54‡C for 1 min and 72‡C for 1 min) and to a ¢nal elongation
(72‡C for 10 min). After puri¢cation on a QIAquick PCR Puri¢cation
column (Qiagen), the PCR products were sequenced, using the Big-
Dye terminator Cycle Sequencing Ready Reaction on an Applied
Biosystem 377 DNA Sequencer.
2.1.2. Rapid ampli¢cation of cDNA ends (RACE). Poly(A)
RNAs were puri¢ed from total chicken lung RNAs with the mRNA
Separator Kit (Clontech). First and second strand cDNA synthesis,
adapter ligation and 5P-RACE or 3P-RACE were performed using the
Marathon cDNA Ampli¢cation kit (Clontech) and the Advantage
cDNA Polymerase Mix (Clontech), as described by the manufacturer.
For both 5P and 3P elongations, two successive reactions were per-
formed, with a ¢rst and a second nested primer, respectively. These
primers were: cEP5-1: 5P-CGGCCCAGCAACTCTTCTGGGTGG-
3P and cEP5-2: 5P-GCGGCTCAGGAAGGTCTTGCT-3P for the 5P-
RACE; and cEP3-1: 5P-CCACCCAGAAGAGTTGCTGGGCCG-3P
and cEP3-2: 5P-GAGAACATGACCAAGAGTCACC-3P for the 3P-
RACE. The ¢rst ampli¢cation reactions consisted of 30 cycles (94‡C
for 30 s and 68‡C for 4 min), whereas the nested ampli¢cations were
carried out with only 18 cycles. After sequencing of the RACE prod-
ucts, the cEPAS1 cDNA was ¢nally generated using Pfu polymerase
(Promega) with the following primers: cEP-ATG: 5P-GGGGTACC-
GCCGCGTGACAGCTGACAAGG-3P and cEP-TGA: 5P-GTCTA-
GAATATTGCAGGATTGCTCAGGTTGCC-3P and cloned in a
pcDNA3.1zeo+ vector (Invitrogen) between the KpnI and XbaI re-
striction sites.
2.2. In situ hybridization (ISH)
In situ hybridization was performed as described previously [21].
Brie£y, embryos were ¢xed in freshly prepared 4% paraformaldehyde
in phosphate bu¡ered saline (PBS), dehydrated in a graded series of
ethanol solutions and embedded in Paraplast. Sections of 5^7 Wm
thick were mounted on silanized slides. For hybridization, the sections
were depara⁄nized and rehydrated, subjected to a microwave heating
treatment for signal enhancement [21], digested with proteinase K
(20 Wg/ml), post¢xed in 4% paraformaldehyde, and dehydrated in
ethanol. Single strands sense and antisense [35S]RNA probes were
generated by in vitro transcription of a partial cEPAS1 clone (nucleo-
tides 251^1438) in pCRII (Invitrogen) using [35S]UTP and SP6 or T7
polymerase. Hybridization was performed overnight at 50‡C. Slides
were washed in increasing stringency solutions and non-hybridized
probes were hydrolyzed by RNase A (20 Wg/ml). After dehydration,
slides were dipped in NTB2 emulsion (Kodak), exposed in the dark
for 2 weeks, photographically developed and counterstained with tol-
uidine blue.
2.3. Immunohistochemistry (IHC)
Sections were depara⁄nized, rehydrated, washed in PBS and non-
speci¢c binding was blocked with 3% normal goat serum in PBS. An
anti-tyrosine hydroxylase antibody (Institut Jacques Boye, Reims,
France) was used at a 1/1500 dilution in 1% normal goat serum
(1.5 h at room temperature), followed by a secondary antibody
(goat biotinylated anti-rabbit IgG 1/200, 45 min) and by ampli¢cation
with the avidin-biotin complex (ABC Elite, Vector, Burlingame, CA,
USA) for 45 min. The peroxidase reaction was then developed with
0.5 mg/ml diaminobenzidine tetrahydrochloride (DAB) in Tris (pH
7.6, 50 mM), and 0.03% H2O2 for 10^15 min. The slides were washed
in Tris (pH 7.6, 50 mM) for 10 min, dehydrated and mounted in
Eukitt.
2.4. Double labeling (ISH+IHC)
The ISH protocol was performed as described above, but inter-
rupted in NaCl-TE, before the ¢nal wash in 0.1 SSC which was
Fig. 1. Sequence alignment of (C) chicken (GenBank accession number AF129813), (H) human, (M) mouse and (B) bovine EPAS1 proteins.
Only di¡erences with the chicken EPAS1 are shown. Functional domains are indicated with boxes in dark gray for bHLH, light gray for PAS
and plain for activation domains.
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replaced by PBS and the IHC protocol was carried out with a ¢nal
wash in Tris (pH 7.6, 50 mM) overnight. After dehydration, slides
were dipped in NTB2 emulsion (Kodak), exposed in the dark for
2 weeks, developed and mounted in Eukitt.
3. Results
3.1. Cloning of chicken EPAS1 cDNA
In order to identify the avian homologue of the bHLH-PAS
transcription factor EPAS1, we performed RT-PCR with con-
served primers on RNAs extracted from chicken lung. A 160
bp fragment, located into the PAS-B domain was ampli¢ed. It
presented 88% homology with the human EPAS1 sequence in
nucleotides, and 100% identity in amino acids. This sequence
was therefore used to design a speci¢c primer, and this ¢rst
fragment was elongated by 5P- and 3P-RACE. We have se-
quenced 3112 bp of the chicken EPAS1 (cEPAS1) cDNA,
which contains a putative open reading frame of 2604 bp.
Translation of this open reading frame into amino acids pre-
dicts a 868 residues protein, with high sequence identities to
human, bovine and mouse EPAS1 (76%, 74% and 72% overall
identity respectively; Fig. 1). As expected, sequence compar-
ison revealed a striking similarity between avian and mamma-
lian EPAS1 in the amino-terminal half, including bHLH
(97%) and PAS (93%) motifs. While most of the sequence in
the C-terminal half is variable between the di¡erent animal
species, a high homology stretch is observed in the last 57
amino acids (90%), in a conserved region shown to contain
a hypoxia-responsive transcriptional activation domain [22].
Interestingly, a Q-rich activation domain, characteristic of
bHLH-PAS proteins, was identi¢ed in the chicken sequence
whereas it is not present in mammalian EPAS1. A Northern
blot experiment revealed a single band of cEPAS1 mRNA at
approximately 6.5 kb (data not shown).
3.2. Expression of EPAS1 during chicken embryogenesis
We studied the expression pattern of the transcription fac-
tor cEPAS1 by in situ hybridization, between day 1 (E1) and
13 (E13) of chick development.
3.2.1. Vascular system The earliest expression of cEPAS1
was detected in four somite embryos (corresponding to Ham-
burger and Hamilton’s stage 8 [23]) in the extra-embryonic
ectoderm, and in the embryo proper at stage 13, in the ECs
of the dorsal aorta (Fig. 2A). At later stages, a strong hybrid-
ization signal was observed in almost every blood vessel of the
embryo, including intersegmental vessels, dorsal aorta (Fig.
2B), sprouting vessels of the neural tube (Fig. 2C), brain
capillaries (Fig. 2D), vessels of the choroid plexus epithelium,
or capillaries in the lung bud (Fig. 2E). Apart from the no-
ticeable exception of the cardinal veins which lack cEPAS1 in
their wall (Fig. 2B), this signal was present in all kinds of
vessels, with no restriction of size, type or localization in the
embryo. Within the vessel wall, cEPAS1 mRNA was detected
predominantly in ECs and, to a lesser degree, in surrounding
pericytes or vascular smooth muscle cells (VSMCs). This lat-
ter signal was observed in most cases in the inner layer(s) of
VSMCs. However, in some large arteries, the labeling could
also be localized throughout the whole vessel wall, with a
stronger intensity in the outer cell layers (adventitia) (Fig.
2F). Interestingly, we observed a loss of cEPAS1 expression
in hematopoietic cells, sprouting from the ventral region of
the dorsal aorta at E3 (data not shown).
3.2.2. Sympathetic nervous system Considering the gene
inactivation of EPAS1 which results in a decrease of catechol-
amine levels, the expression of cEPAS1 in sympathetic neu-
rons and ganglia was studied in detail. We compared the ex-
pression of this transcription factor, detected by ISH, to that
of TH, a putative target of EPAS1 in this system, revealed by
IHC. Starting at E4, expression of cEPAS1 was observed in
the para-aortic ganglia forming the primary sympathetic
chain, visible at that early stage as two rows of cells ventral
to the somites and immediately lateral to the aorta. TH pro-
tein was also detected in the same cells (shown at E5 in Fig.
3A). Then, this coexpression continued at E5^E6 at least in
Fig. 2. Vascular expression of cEPAS1 in the chicken embryo. In
situ hybridization signal is observed under dark ¢eld illumination.
Note the expression of cEPAS1 at stage 13 (A) in the ectoderm of
the extra-embryonic area (arrowheads) and in ECs of dorsal aorta
(insert). At stage 24 (B), cEPAS1 is present in dorsal aorta (da), but
not in cardinal veins (cv). During development, the vascular expres-
sion of cEPAS1 remains very intense in all blood vessels and capil-
laries as in neural tube (C) and brain (D) at day 6 or lung bud (E)
at day 8. Note that although cEPAS1 is always expressed in ECs, it
can also be present in VSMCs (F). Bar: 200 Wm (A, C, D, E);
100 Wm (B, F).
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the secondary chain migrating to form the medullary plexus of
the adrenal gland and a double labeling experiment con¢rmed
that cEPAS1 and TH were indeed expressed in the very same
cells (Fig. 3C). However, at the caudal level, a large conden-
sation of cEPAS1-positive cells, ventral to the aorta, appeared
TH-negative (Fig. 3B). At E8, a cEPAS1 hybridization signal
was detected together with the TH immunoreactivity in the
chroma⁄n tissues within the adrenal gland (Fig. 3D). Finally,
at E9 and E13, the expression of cEPAS1 mRNA was ob-
served in all TH-positive ganglia and in sympathetic neurons
innervating mesenteric arteries (Fig. 3E).
3.2.3. Miscellaneous. In the heart (Fig. 4A), cEPAS1 was
strongly positive in the endocardium, in both the ventricles
and the atria. At the tip of the valves, the hybridization signal
was particularly intense in endocardial cells and extended be-
neath, in the mesenchymal cells at the site of putative epithe-
lial-mesenchymal transformation [24,25].
A very strong expression of cEPAS1 was observed in the
liver. At E3.5, it was detected in ECs of the sinusoids and it
appeared at day 5 in hepatocytes, although less intensely.
From E6 to E13, these two cell types presented very high
and comparable levels of expression of cEPAS1 transcripts
(Fig. 4B).
In the mesonephros as well as in the metanephros, the ex-
pression of cEPAS1 was detected, from E3 and E10 onward
respectively, within the glomerulus (Fig. 4C). Even though it
is di⁄cult to identify the type of the positive cells, it is likely
that cEPAS1 transcripts are present in both endothelial and
mesangial cells, but not in podocytes where VEGF is strongly
expressed (data not shown).
4. Discussion
In this study, we describe the cloning and the expression
pattern of the chicken EPAS1 transcription factor. Its de-
duced amino acid sequence is very close to its mammalian
homologues, in particular in the functional motifs bHLH,
PAS and activation domains located in the amino-terminus
or carboxy-terminus of the variable region [22]. We performed
a detailed study of the expression pattern of cEPAS1 mRNA
during chicken development and our results reveal, in addi-
tion to the expected vascular sites of expression, a close topo-
graphical association with the sympathetic nervous system.
cEPAS1 mRNA appears in the extra-embryonic area where
it is localized mostly in the ectodermal layer, in cells known to
express VEGF [26] which is a putative target gene for EPAS1
[4]. This ectoderm has been shown to inhibit hemangioblast
Fig. 3. Expression of cEPAS1 and tyrosine hydroxylase in the sym-
pathetic nervous system. At E5, EPAS1 and TH are coexpressed in
para-aortic ganglia (arrows) (A). At this stage, cEPAS1 is also
present in mesenchymal cells in between. In the migrating sympa-
thetic chain, cEPAS1 expression can be observed at the caudal level,
earlier than that of TH, as shown at day 5 (B). Double labeling ex-
periments con¢rm that cEPAS1 and TH are expressed in the very
same cells of the sympathetic chain at E6 (C). In the adrenal gland,
both cEPAS1 and TH are present in chroma⁄n cells at E8 (D) and
are also coexpressed in neurons innervating a mesenteric artery at
E13 (E). A, B and D: Observation of TH labeling (left column) and
cEPAS1 hybridization signal by dark ¢eld illumination (right col-
umn). C and E: Double labeling cEPAS1-TH observed in bright
¢eld. NT: neural tube; N: notochord; DA: dorsal aorta; K: kid-
ney. Bar: 100 Wm (A, B, D); 25 Wm (C, E).
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induction, and permits the emergence only of angioblasts
from the adjacent dorsal (somitic) mesoderm [27]. These ob-
servations, together with the loss of cEPAS1 expression in
hematopoietic progenitors sprouting from the ventral region
of the dorsal aorta at E3, suggest that if cEPAS1 is involved
in angiogenesis, it would be related to the angioblastic and not
to the hemangioblastic lineage. In the developing embryo,
cEPAS1 appears to be expressed in all blood vessels, with
the exception of the cardinal veins. As described in the mouse
[2,5,12], we could localize this expression, at a very high level,
in chick ECs of the vessel wall. However, we show here that in
some vessels such as large arteries, cEPAS1 mRNA is also
present in pericytes and/or VSMCs, where it may be coex-
pressed together with VEGF [28]. The presence or absence
of cEPAS1 in these cells could not be related to any func-
tional, topographical or morphological characteristics. The
vascular expression of cEPAS1 in both ECs and VSMCs sup-
ports the results obtained in vitro demonstrating that EPAS1
transactivates genes expressed in both cell types, respectively
Tie2 [2] or Flk1 [16] and VEGF [4]. These observations are in
keeping with the hypothesis of a major regulatory role for
EPAS1 at the interconnection of several pathways of blood
vessel formation or remodeling. Although minor defects can-
not be excluded, one should then assume that the absence of
the vascular phenotype reported in EPAS13/3 mice [17] is
the consequence of a compensation by other transcription
factors.
Although EPAS1 is most likely involved, at a level which
remains to be determined, in angiogenesis, the knock-out re-
sults unexpectedly pointed to another essential function of this
transcription factor during development. Indeed, it appears
that EPAS1 is necessary for catecholamine release and there-
fore, enzyme(s) involved in catecholamine synthesis may be
targets of EPAS1 during (and after) embryogenesis. The co-
localization of TH and cEPAS1 mRNA within the same gan-
glionic cells, as shown here for the ¢rst time, provides evi-
dence for a possible direct regulatory role of EPAS1 on
catecholamine production. Our results further document the
observations made by Tian et al. on the role of EPAS1 in
catecholamine production [17], as they reveal that TH is
most likely one of the key target genes of EPAS1. Hypoxia
is a major inducer of angiogenesis and also strongly and di-
rectly a¡ects the sympathetic nervous system. Since both an-
giogenic factors and TH harbor HREs in their promoter re-
gion (for review, see [29]), the colocalization of cEPAS1 and
TH in the same cells may represent the missing link that
allows the functional connection and interaction between
two distinct hypoxia-sensitive systems.
In addition, the remarkable intensity of cEPAS1 expression
in ECs and VSMCs raises the question of its function in blood
vessel formation, maturation, or stabilization. Other sites of
cEPAS1 expression (liver, kidney) also suggest new roles of
EPAS1 to be discovered. The chicken embryo model and the
cloning of cEPAS1 mRNA o¡er the opportunity to shed some
light on the intricate relationship between angiogenesis, hyp-
oxia and catecholamine production.
5. Note added in proof
During preparation of this manuscript, another avian ho-
mologue of EPAS1/HIF2K was cloned in quail [Elvert et al.
(1999) Mech Dev. 87, 193^197].
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